Response to Anti-EGFR Therapy in Patients with BRAF non-V600-Mutant Metastatic Colorectal Cancer.
Animals
Cetuximab
/ therapeutic use
Colorectal Neoplasms
/ drug therapy
ErbB Receptors
/ antagonists & inhibitors
Female
Humans
Male
Mice, Inbred NOD
Mice, SCID
Molecular Targeted Therapy
Mutation
Prognosis
Prospective Studies
Protein Kinase Inhibitors
/ therapeutic use
Proto-Oncogene Proteins B-raf
/ genetics
Survival Rate
Tumor Cells, Cultured
Xenograft Model Antitumor Assays
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500
Informations de publication
Date de publication:
01 12 2019
01 12 2019
Historique:
received:
18
06
2019
revised:
14
08
2019
accepted:
15
08
2019
pubmed:
14
9
2019
medline:
22
9
2020
entrez:
14
9
2019
Statut:
ppublish
Résumé
While mutations in BRAF in metastatic colorectal cancer (mCRC) most commonly occur at the V600 amino acid, with the advent of next-generation sequencing, non-V600 BRAF mutations are increasingly identified in clinical practice. It is unclear whether these mutants, like BRAF V600E, confer resistance to anti-EGFR therapy. We conducted a multicenter pooled analysis of consecutive patients with non-V600 BRAF-mutated mCRCs identified between 2010 and 2017. Non-V600 BRAF mutations were divided into functional classes based on signaling mechanism and kinase activity: activating and RAS-independent (class 2) or kinase-impaired and RAS-dependent (class 3). Forty patients with oncogenic non-V600 BRAF-mutant mCRC received anti-EGFR antibody treatment [ Response to EGFR antibody treatment in mCRCs with class 2 BRAF mutants is rare, while a large portion of CRCs with class 3 BRAF mutants respond. Patients with colorectal cancer with class 3 BRAF mutations should be considered for anti-EGFR antibody treatment.
Identifiants
pubmed: 31515458
pii: 1078-0432.CCR-19-2004
doi: 10.1158/1078-0432.CCR-19-2004
pmc: PMC6891165
mid: NIHMS1538023
doi:
Substances chimiques
Protein Kinase Inhibitors
0
EGFR protein, human
EC 2.7.10.1
ErbB Receptors
EC 2.7.10.1
BRAF protein, human
EC 2.7.11.1
Proto-Oncogene Proteins B-raf
EC 2.7.11.1
Cetuximab
PQX0D8J21J
Types de publication
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
7089-7097Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA233736
Pays : United States
Organisme : NCI NIH HHS
ID : R35 CA210085
Pays : United States
Organisme : NIH HHS
ID : U54 OD020355
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
©2019 American Association for Cancer Research.
Références
Nature. 2006 Jan 19;439(7074):358-62
pubmed: 16273091
Ann Oncol. 2019 Jan 1;30(1):147-149
pubmed: 30364934
J Clin Oncol. 2017 Aug 10;35(23):2624-2630
pubmed: 28486044
Lancet Oncol. 2010 Aug;11(8):753-62
pubmed: 20619739
Ann Oncol. 2015 Oct;26(10):2092-7
pubmed: 26153495
Science. 2006 Mar 3;311(5765):1287-90
pubmed: 16439621
Ann Oncol. 2018 Jan 1;29(1):44-70
pubmed: 29155929
J Natl Compr Canc Netw. 2018 Apr;16(4):359-369
pubmed: 29632055
JAMA Oncol. 2017 Feb 1;3(2):194-201
pubmed: 27722750
N Engl J Med. 2007 Nov 15;357(20):2040-8
pubmed: 18003960
Eur J Cancer. 2015 Mar;51(5):587-94
pubmed: 25673558
PLoS One. 2015 Oct 16;10(10):e0140712
pubmed: 26474073
Br J Cancer. 2017 Nov 7;117(10):1450-1458
pubmed: 28972961
J Med Chem. 2018 Jul 26;61(14):5775-5793
pubmed: 29461827
Clin Cancer Res. 2018 Jul 1;24(13):3108-3118
pubmed: 29530932
Cancer Res. 2017 Dec 1;77(23):6513-6523
pubmed: 28951457
Cancer Cell. 2016 Apr 11;29(4):477-493
pubmed: 26996308
Clin Cancer Res. 2014 Feb 1;20(3):744-53
pubmed: 24218517
Ann Oncol. 2017 Aug 1;28(8):1862-1868
pubmed: 28449055
Nature. 2002 Jun 27;417(6892):949-54
pubmed: 12068308
Oncogene. 2018 Mar;37(13):1775-1787
pubmed: 29348459
Cancer Cell. 2018 Mar 12;33(3):450-462.e10
pubmed: 29533785
Proc Natl Acad Sci U S A. 2014 Oct 21;111(42):15155-60
pubmed: 25288756
Nature. 2010 Mar 18;464(7287):427-30
pubmed: 20179705
Nature. 2015 Oct 8;526(7572):263-7
pubmed: 26416732
Cell. 2010 Jan 22;140(2):209-21
pubmed: 20141835
Cancer Discov. 2019 Mar;9(3):329-341
pubmed: 30770389
Cell. 2004 Mar 19;116(6):855-67
pubmed: 15035987
J Clin Oncol. 2010 Jan 20;28(3):466-74
pubmed: 20008640
Eur J Cancer. 2012 Jul;48(10):1466-75
pubmed: 22446022
Ann Oncol. 2016 Aug;27(8):1386-422
pubmed: 27380959
J Mol Diagn. 2011 Jan;13(1):64-73
pubmed: 21227396
Ann Oncol. 2017 Aug 1;28(8):1713-1729
pubmed: 28407110
Cancer Cell. 2018 Jan 8;33(1):125-136.e3
pubmed: 29316426
Cancer Cell. 2015 Sep 14;28(3):370-83
pubmed: 26343582
Lancet Oncol. 2013 Jul;14(8):749-59
pubmed: 23725851
Nat Rev Cancer. 2017 Nov;17(11):676-691
pubmed: 28984291
Oncologist. 2017 Jul;22(7):864-872
pubmed: 28576857
Nat Rev Cancer. 2014 Jul;14(7):455-67
pubmed: 24957944
Ann Oncol. 2017 Nov 1;28(11):2648-2657
pubmed: 29045527
Br J Cancer. 2015 Jun 9;112(12):1888-94
pubmed: 25989278
Nature. 2017 Aug 10;548(7666):234-238
pubmed: 28783719
Cancer Discov. 2013 Jun;3(6):658-73
pubmed: 23729478
J Mol Diagn. 2015 May;17(3):251-64
pubmed: 25801821